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Abstract  
 
 
Background and Objectives 
Identifying patients who may develop acute kidney injury (AKI) remains 
challenging as clinical determinants explain only a portion of individual risk.  
Another factor that likely affects risk is intrinsic genetic variability.  Therefore, 
we performed a systematic review of studies that related the development or 
prognosis of AKI to genetic variation.   
 
Design 
We searched MEDLINE, EMBASE, HuGEnet, SCOPUS and Web of Science for 
articles from 1950 to Dec 2007.  Two independent researchers screened articles 
using predetermined criteria.  Studies were assessed for methodological quality 
via an aggregate scoring system. 
 
Results 
The 16 included studies were of cohort or case-cohort design, and investigated 35 
polymorphisms in 21 genes in association with AKI.  Fifteen gene-gene 
interactions were also investigated in 4 separate studies.  Study populations were 
primarily premature infants or adults who were critically ill or post-cardiac 
bypass.  Among the studies, 5 different definitions of AKI were used.  Only 1 
   
polymorphism, APO E e2/e3/e4, had greater than one study showing a significant 
impact (p<0.05) on AKI incidence while of gene-gene interactions, this was true 
only with the IL-6 -174G/C and TNF- -308G/A combination .  The mean quality 
score of 5.8/10 (range 4-9), heterogeneity in the studies and the dearth of studies 
precluded additional meta-analysis of the results.  
 
Conclusions 
Current association studies are unable to provide definitive evidence linking 
genetic variation to AKI.  Future success will require a narrow consensus 
definition of AKI, rigorous epidemiologic techniques and a shift from a priori 
hypothesis-driven to genome-wide association studies. 
 
Keywords: 
 
Acute Kidney Injury, Acute Renal Failure, Genetic Polymorphism, Single 
Nucleotide Polymorphism, Gene-gene Interaction, Genetic Susceptibility to 
Disease, Genetic Association Study, Genome-Wide Association Study  
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1 
Introduction 
 
Acute kidney injury (AKI) is a complex disorder manifested by a rapid loss of 
renal function that results in retention of metabolic waste products.(1)  A disease 
that primarily afflicts hospitalized patients, the incidence of AKI has steadily 
increased over the past decade, and while mortality has fallen with advances in 
renal replacement therapy (RRT), AKI still confers significant morbidity and 
mortality.(2-4)  Several recent large studies of medical administrative databases 
have shown that in-hospital mortality for patients who develop AKI ranges from 
20-28%; for those who require RRT, the mortality is higher, ranging from 28-
33%.(3-5)  Currently, there are no effective therapies to treat AKI.  The present 
standard of care is to remove any potential instigating factors, optimize volume 
status and provide supportive care to allow renal function to recover.(1)  As 
such, the ability to identify high-risk patients and potentially prevent AKI 
becomes crucial. 
 
The current literature maintains that a patient’s risk for AKI depends on a 
combination of acute insults and chronic co-morbidities.  Acute risk factors 
include volume depletion, exposure to nephrotoxic agents or drugs such as 
aminoglycosides or radiocontrast dye, surgery, and the presence of the systemic 
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inflammatory response syndrome or sepsis.(6-9) Chronic risk factors include 
advanced age, chronic kidney disease (CKD), diabetes and congestive heart 
failure.(9, 10)  However, models using these traditional risk factors remain 
inadequate.(6, 7, 11-14) Two patients with identical clinical risk factors often react 
differently to the same insult; one may suffer no harm while the other may 
require RRT.  Furthermore, for those who develop RRT-requiring AKI, we as 
clinicians remain unable to predict which patients will progress to chronic 
dialysis and which will recover kidney function. 
 
Consequently, there are likely to be clinically unobservable risk factors that 
contribute to one’s susceptibility to AKI.  Our understanding of epithelial, 
vascular and immune responses in kidney injury makes it likely that genetic 
variability in regulatory elements of these responses plays a major role in 
determining one’s risk of AKI, given identical risk factors.  This has been seen in 
other complex diseases, such as the discovery of a single nucleotide 
polymorphism (SNP) in complement factor H as a risk factor for age-related 
macular degeneration.(15)  While there have not been any animal studies looking 
specifically at genetic polymorphisms and their impact on an organism’s 
response to AKI, there has been strong evidence for differential gene expression 
in the murine model of AKI.(16)  A genetic polymorphism that would alter that 
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pattern of gene expression would hence change the reaction of an organism or 
individual cell to an acute insult, thus making such polymorphisms a plausible 
risk factor for AKI. 
 
In AKI, genetic variation in inflammatory cytokines such as Tumor Necrosis 
Factor-alpha (TNF-) and Interleukin-6 (IL-6) have recently been proposed as 
risk factors.(13, 17-20) This is due to the role of inflammatory mediators in the 
pathophysiology of AKI, especially with ischemia and sepsis.(1, 21, 22) Genetic 
variations of vasomotor regulatory proteins, such as angiotensin converting 
enzyme (ACE) and endothelial nitric oxide synthase (eNOS), have also been 
investigated given the importance of vascular reactivity in the pathogenesis of 
AKI.(13, 21, 23-25) 
 
However, it remains difficult to ascertain which polymorphisms are truly 
associated with AKI.(26)  False positive reports are common in genetic 
association studies, and the plausibility of an association is highly dependent on 
the quality of the studies involved.(27) Therefore, we conducted this systematic 
review to evaluate the quality of published studies on genetic associations with 
AKI, and to ascertain if the current evidence demonstrates any polymorphism to 
be conclusively associated with AKI. 
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Hypothesis and Aims 
 
The primary hypothesis of this study is as follows, that a given patient’s risk of 
developing acute kidney injury after a known insult, such as ischemia, sepsis or 
nephrotoxic agents, is dependent on that patient’s genetic makeup.  That is, 
genetic polymorphisms that are commonly found in the population at large will 
render a patient either more or less susceptible to AKI.  Our aim is to do a 
systematic review of the current existing literature on the topic and, where 
possible, perform a quality analysis of the studies found in order to determine 
the plausibility of the reported associations.  Where appropriate, we plan to 
perform a meta-analysis to provide pooled odds ratios and relative risks. 
 
Methods 
 
Literature Selection 
 
Studies were selected by searching MEDLINE, EMBASE, HuGEnet, SCOPUS and 
Web of Science for articles listed from 1950 up until December 2007.  We used 
terms such as “acute kidney injury”, “acute renal insufficiency” and “acute renal 
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failure” in combination with “genetic variation” and “polymorphism” as our 
search criteria.  We included many terms in our search to achieve as high 
sensitivity as possible.   
 
Search terms were chosen by using keywords found in the Medical Subject 
Headings (MeSH) controlled language.  This is the search language that is used 
by MEDLINE to index all articles found within that database.  The MeSH 
language tree was searched for any and all keywords or categories associated 
with AKI or genetics.  Where possible, we excluded more specific terms by 
moving up the MeSH language tree in order to use more inclusive search terms.  
For example, “genetic polymorphism” was included under “variation 
(genetics)”, and “acute tubular necrosis” was included within “acute kidney 
failure.”  EMBASE search terms were found by matching MeSH terms to their 
equivalent EMTREE terms, a different controlled language that is used within 
the EMBASE database.    Web of Science, SCOPUS and HuGEnet do not use 
controlled languages and therefore a larger number of relevant keywords were 
used.  Our exact criteria are listed in Table 1 below. 
 
 
 
 
   
6 
Table 1 | Search criteria     
              
MEDLINE       
Anuria, acute kidney failure, acute renal insufficiency, uremia, oliguria, creatinine, acute  
nephropathy or acute kidney injury     
AND       
Gene frequency, genotype, phenotype, variation (genetics), gene expression, gene expression 
regulation, genes or nucleic acid regulatory sequences   
       
EMBASE       
Oliguria, creatinine blood level, creatinine, creatinine clearance, anuria, uremia, kidney tubule 
necrosis, acute kidney failure, acute kidney tubule necrosis, kidney dysfunction, acute nephropathy 
or acute kidney injury      
AND       
Allelism, genetic heterogeneity, genotype, human genetics, mutation, phenotype, population 
genetics, population genetic parameters, gene expression or gene  
       
Web of Science, SCOPUS and HuGEnet    
Acute renal insufficiency, acute nephropathy, acute kidney injury, acute tubular necrosis, acute 
kidney failure, kidney dysfunction or acute renal failure   
AND       
Gene frequency, genetic frequency, genotype, phenotype, gene variation, genetic variation, gene 
expression, genetic expression, polymorphism, nucleic acid regulatory sequences, allelism, 
genetic heterogeneity, mutation or population genetics   
 
 
A strict set of selection criteria were then applied to the articles found by the 
search.  We included any original study that pertained to associations between 
AKI and human gene polymorphisms or variability. Our exclusion criteria were 
the following: 1) Studies with less than 20 subjects; 2) Case reports and series; 3) 
Animal studies; 4) Outpatient studies; 5) Studies where the etiology of AKI was 
HUS/TTP, ischemia/reperfusion of a kidney allograft, IgA nephropathy or 
glomerulonephritis. 
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The reasons for each of the exclusion criteria are as follows.  For criteria 1), the 
effect found in a study with fewer than 20 subjects was as likely to be from 
chance as an actual effect, despite achieving statistical significance.  Therefore, all 
such small studies were excluded.  Likewise, case reports and series would likely 
have small numbers and also would not be able to show an association, given 
that no comparison would have been made to a control group or an at risk 
population.  Animal studies were excluded because we were interested primarily 
in how human genetic heterogeneity contributed to the risk of AKI.  Outpatient 
studies were excluded as AKI is primarily a disease of hospitalized patients.  
Finally, the final criterion was included as we hoped to capture studies of AKI 
from ischemia or nephrotoxic injury, which are the commonest causes of AKI in 
hospitalized settings. 
 
The titles and abstracts of the articles found by our search were screened using 
our selection criteria and articles of interest were selected for full article 
evaluation (figure 1); the bibliographies of relevant articles were also searched.  
Full articles were then reviewed by two researchers (JL and UP) independently 
and a final selection was made; disagreements were discussed and a consensus 
decision was reached as to whether or not to include an article. On one article 
pertaining to AKI in preeclampsia(28), our discussion was inadequate to achieve 
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consensus and a third researcher (CP) evaluated the study, which resulted in its 
exclusion. 
 
Data Abstraction 
 
The following data were extracted from each study: first author, journal, year of 
publication, number of cases/controls, ethnicity and the clinical setting in which 
AKI occurred. The gene polymorphisms or combinations thereof investigated by 
each of the studies were recorded, and the conclusions of the authors noted.  
Primary and secondary endpoints of each study were recorded as well. Study 
quality parameters were also collected.  Studies were scored in 10 categories, 
which are described in table 2 below.  Each study then received an aggregate 
quality score using a system adapted from Clark et al.(29)  Cohort studies were 
automatically given one point in the control group category to facilitate 
comparison; this was deemed acceptable as cohort studies are better for studying 
high prevalence conditions such as AKI.  A study was scored as ‘good’ if the 
score was 8-10, ‘fair’ if the score was 5-7 and ‘poor’ if the score was <4. 
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Table 2 | Scoring system for study quality used in this systematic review  
Quality Criterion Explanation Scoring 
Control Group Was the control group equal or larger than the case group, Yes=1 
 and can it be replicated from the description given?  No=0 
 Cohort studies were automatically given a point.  
Hardy-Weinberg Were the case and control groups assessed for Hardy- Yes=1 
Equilibrium Weinberg Equilibrium? No=0 
Case Group 
Can the case group be replicated from the description given, 
and Yes=1 
 was the disease state of interest adequately defined? No=0 
Primer Was the primer sequence used for genotyping or a reference  Yes=1 
 to one provided? No=0 
Reproducability 
Can the genotyping method be reproduced from the 
description Yes=1 
 given, and was the method validated via a second technique? No=0 
Blinding Were the researchers performing the genotyping blinded to  Blinded=1 
 the clinical status of the patient? Not blinded = 0 
Power  Was a power calculation performed?   Yes=1 
Calculation  No=0 
Statistics Were the major findings presented with well described tests of Yes=1 
 tests of significance? No=0 
Corrected If a study examined two or more polymorphisms, were the  Corrected=1 
Statistics 
statistics corrected for the increased risk of a false-positive 
finding? No correction=0 
Independent Was a second, confirmatory study performed? Yes=1 
Replication  No=0 
 
 
Our initial research proposal also included a plan to pool odds ratios and relative 
risks for individual genetic polymorphisms in a meta-analysis.  Pooling of results 
was not undertaken, however, primarily because of marked heterogeneity in 
study populations as well as the definition of AKI for studies of specific genetic 
polymorphisms. 
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Results 
 
Our search returned 7273 unique articles, of which 43 were retrieved for full 
article review based upon our screening of titles and abstracts.  Reasons for the 
exclusion of studies can be found in figure 1.  Of those that required full article 
review, only 16 articles met our eligibility criteria and were included in the 
analysis; initial inter-reviewer agreement on article selection was excellent 
(40/43).  Overall, these 16 articles investigated 21 candidate genes and 35 separate 
polymorphisms in association with AKI.  Four studies investigated the role of 
gene-gene interactions (i.e. combinations of polymorphisms) describing 15 
different combinations and their association with AKI.  Of the 21 genes studied, 7 
involved inflammatory pathways, 5 with oxidative stress or ischemia, 4 with 
vasomotor regulation, 2 with drug metabolism and 1 each involved in 
angiogenesis, coagulation regulation and cholesterol metabolism. 
 
Of the 16 included studies, 14 described genetic associations with AKI incidence 
(Table 3a) while 2 analyzed AKI outcomes (Table 3b). All studies had a cohort or 
case-cohort design; 11 were prospective studies. All study populations were of 
mixed gender; 12 studies investigated adults, while 4 studied neonates. Only 9 of 
16 studies reported the ethnicity of their populations.  The clinical setting where  
   
Table 3a | Characteristics of Studies Examining Genetic Risk Factors for AKI Incidence     
Article (author, 
year) Type of study Site Gene Polymorphism(s) studied # of 
# of 
AKI Study 
Clinical 
Setting Ethnicity % Definition of AKI or Quality 
        patients cases Population     Caucasian clinical variable studied Score 
Banyasz 2006 Retrospective SC VEGF -2578 C/A, +405 G/C,  128 41 
VLBW 
infants Critically ill NR … Modi 1999† 5 
  case cohort   -460 T/C                 
Chew 2000 Prospective SC APO E e2/e3/e4 564 ...* Adults Post-CPB NR … Delta Cr 7 
  cohort                     
Fekete 2003 Retrospective SC HSP72 +1267 A/G 120 37 
VLBW 
infants Critically ill Hungarian 100 Modi 1999 5 
  case cohort   HSP73 +190 G/C         Ethnicity       
Gordon 2004 Prospective MC TNF-a -238 G/A, -308 G/A 213 … Adults Critically ill  Caucasian 100 SOFA renal score 9 
 cohort  LTA +365 C/G, +249G/A    with sepsis     
   TNFRSF1A +1135 C/T, +36 A/G,          
   -609 G/T         
      TNFRSF1B +1663 A/G, +676 T/G                 
Guadino 2002 Prospective SC IL-6 -174 G/C 111 … Adults Post-CPB NR … Delta Cr 6 
  cohort                     
Isbir 2007 Prospective NR ACE I/D 248 54 Adults Post-CPB NR … Bellomo 2004 (RIFLE)‡ 4 
 case cohort  APO E e2/e3/e4         
      AGTR1 +1166 A/C                 
Luo 2004 Prospective SC Haptoglobin phenotype  148 27 Adults Post-CPB Chinese, 0 Nash 2002§ 4 
 cohort  (Hp2-2 vs (Hp2-1 and Hp1-1))     Malay    
                Indian       
MacKensen 2004 Prospective NR APO E e2/e3/e4 130 … Adults Post-CPB Mixed NR Delta Cr 7 
  cohort                     
Nobilis 2001 Retrospective SC ACE I/D 110 42 
VLBW 
infants Critically ill NR … Modi 1999 4 
  case cohort   AGTR1 +1166 A/C                 
*Studies that looked at continuous outcome variables did not define cases 
† Modi 1999 definition of AKI: serum Cr > 120 umol and/or serum urea > 9 mmol/L, and diuresis of 1.0 mL urine/kg/hr 
‡ Bellomo 2004 (RIFLE) definition of AKI: increase in serum creatinine of 50% or greater 
§ Nash 2002 definition of AKI: delta Cr > 0.5mg/dL from baseline of 1.9mg/dL or less, 1.0mg/dL from baseline of 2.0 to 4.9mg/dL and 1.5mg/dL for patients with baseline >5.0 mg/dL 
Abbreviations: NR= not reported; SC= single centre; MC= multicentre; VLBW = very low birth weight; CPB = cardiopulmonary bypass; Delta Cr = change in serum creatinine in mg/dL 
 
 
 
   
Table 3a continued | Characteristics of Studies Examining Genetic Risk Factors for AKI Incidence    
Article (author, year) Type of study Site Gene Polymorphism(s) studied # of 
# of 
AKI Study 
Clinical 
Setting Ethnicity % Definition of AKI or Quality 
        patients cases Population     Caucasian clinical variable studied Score 
Stafford-Smith 2005 Prospective SC ACE I/D 1671 … Adults Post-CPB Caucasian, 88 Delta Cr 8 
 cohort  Angiotensinogen +842 T/C     African-    
   AGTR 1 +1166 A/C     American    
   eNOS +894 G/T         
   IL-6 -174 G/C, -572 G/C, -597 G/A         
   TNF-a +488 G/A, +376 G/A, -308 G/A        
   APO E +448 T/C (APOE e4)         
      APO E +586 C/T (APOE e2)                 
Sirgo 2004 Prospective SC PAI-1 4G/5G 150 11 Adults Post-CPB Caucasian 100 Doubling of Cr 4 
 cohort            
Treszl 2002 Retrospective SC TNF-a -308 G/A 92 36 
VLBW 
infants Critically ill NR … Modi 1999 7 
 case cohort  IL-1b +3954 C/T    with sepsis     
   IL-6 -174 G/C         
   IL-10 -1082 G/A          
Wattanathum 2005 Prospective SC IL-10 haplotype 158 ...* Adults Critically ill Caucasian 100 # of days free of renal 5 
  cohort   (-592 C/A, -1082 A/G,+3367 G/A)       with sepsis     dysfunction   
Woodahl 2007 Retrospective SC ABCB1 +1236C/T, +2677 G/T/A 121 48 Adults Post-HCT NR … Doubling of Cr 6 
  cohort   +3435 C/T,+1199 G/A                 
*Studies that looked at continuous outcome variables did not define cases         
Abbreviations: NR= not reported; SC= single centre; MC= multicentre; VLBW = very low birth weight; HCT = hematopoietic cell transplantation; Cr = creatinine  
            
Table 3b | Characteristics of Studies Examining Genetic Risk Factors for AKI Outcome     
Article (author, year) Type of study Site Gene Polymorphism(s) studied # of 
# of 
AKI Study 
Clinical 
Setting Ethnicity % Definition of AKI or Quality 
        patients cases Population     Caucasian clinical variable studied Score 
Perianayagam 2007 Prospective MC NADPH Oxidase p22phox +242C/T 200 200 Adults Hospitalized Mixed 90 Dialysis or mortality 7 
 cohort  Catalase -262 C/T          
Jaber 2004 Prospective MC TNF-a -308 G/A 61 61 Adults Hospitalized Mixed 93 Mortality and recovery 5 
  cohort   IL-10 -1082 A/G             of renal function   
Abbreviations: MC = multicentre           
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AKI was studied fell primarily into two groups, post-cardiopulmonary bypass (7 
studies) and critically ill with or without sepsis (6 studies). Of the remaining 
studies, two investigated all hospitalized patients with AKI, while one study 
investigated patients after hematopoietic cell transplant.  AKI in all studies was 
caused by ischemia/reperfusion, sepsis or nephrotoxic agents. 
 
The definition of AKI varied greatly in the included studies, as no fewer than 5 
different definitions of AKI were used.(10, 30, 31) In addition, 4 studies opted to 
report only the change in serum creatinine;  only the study by Stafford-Smith et 
al. stated a reason for doing so, that being the lack of a consensus definition for 
AKI at the time of the study.  Two studies used hard endpoints of dialysis or 
mortality.  The quality of studies was generally mediocre; mean quality score 
was 5.8/10 (range 4-9).  Four studies were scored as ‘poor’, 10 were ‘mediocre’ 
while only 2 were of ‘good’ quality.  Primarily, studies were lacking in the areas 
of reproducibility of genotyping methods, blinding, power calculations, 
corrected statistics for multiple comparisons and independent replication of 
results (Figure 2).(29)  
 
Table 4 describes the specific polymorphisms studied and the authors’ 
conclusions. In summary, nine polymorphisms (NADPH Oxidase p22phox 
   
 
Table 4 | Gene characteristics        
Gene Polymorphism Chromosome Functional Type of  Study Author's conclusion Comparison Association Magnitude of Significance 
   significance polymorphism  on association  Variable association of association 
            with AKI         
APO E  e2/e3/e4 19q13 Cholesterol metabolism SNP Isbir 2007 Yes e4 vs. non-e4 AKI OR=0.18† p=0.002 
 e2/e3/e4    MacKensen 2004 Yes e4 vs. non-e4 Delta Cr … p=0.82 
 e2/e3/e4    Chew 2000 Yes e4 vs. e2, e3 Delta Cr … p=0.038, p=0.015 
 e2/e3/e4    Stafford-Smith 2005 No e4 vs. non-e4 Delta Cr … p=0.009*‡ 
 e2/e3/e4    Stafford-Smith 2005 No e2 vs. non-e2 Delta Cr … p=0.32§ 
NADPH Oxidase +242C/T 16q24 Oxidative stress SNP Perianayagam 2007 Yes CT/TT vs. CC Dialysis or mortality OR=2.11 p=0.01 
     p22phox           
Catalase -262 C/T 11p13 Oxidative stress SNP Perianayagam 2007 No CT/TT vs. CC Dialysis or mortality OR=1.05 p=0.86 
ACE I/D 17q23 Vasomotor regulation Intron deletion Isbir 2007 Yes ID/DD vs. II AKI  OR=2.37† p=0.021 
 I/D    Stafford-Smith 2005 No II/ID vs. DD Delta Cr … p=0.004* 
 I/D    Nobilis 2001 No I vs. D allele AKI … NS 
AGT +842 T/C 1q42 Vasomotor regulation SNP Stafford-Smith 2005 No CC/CT vs. TT Delta Cr … p<0.0001*; 0.99|| 
AGTR1 +1166 A/C 3q21-25 Vasomotor regulation SNP Isbir 2007 No AA vs. AC/CC AKI OR=1.09† p>0.05 
 +1166 A/C    Stafford-Smith 2005 No CC/CA vs. AA Delta Cr … p=0.84$ 
 +1166 A/C    Nobilis 2001 No C vs. A allele AKI … NS 
 +1166 A/C    Li 2007 No AA vs. AC/CC AKI OR=0.34† p=0.116 
eNOS  +894 G/T 7q36 Vasomotor regulation SNP Stafford-Smith 2005 No TT/TG vs. GG Delta Cr … p=0.17; 0.04*|| 
ABCB1 +1236 C/T 7q21 Drug metabolism SNP Woodahl 2007 No TT vs. CC/CT AKI OR=1.9 p=0.21 
 +2677 G/T/A    Woodahl 2007 No TT vs. GG/GT AKI OR=1.6 p=0.34  
 +2677 G/T/A    Woodahl 2007 No TT vs. TA/GA AKI OR=2.5 p=0.33  
 +3435 C/T    Woodahl 2007 No TT vs. CT/CC AKI OR=1.1 p=0.82 
 +1199 G/A    Woodahl 2007 No GG vs. GA/AA AKI OR=3.2 p=0.14 
CYP3A5   *1/*3 7q21 Drug metabolism Splice variant Woodahl 2007 No *3/*3 vs.   AKI OR=0.8 p=0.68 
       *1/*3 + *1/*1    
HSP72  +1267 A/G 6p21 Ischemia tolerance SNP Fekete 2003 Yes GG vs. GA/AA AKI OR=3.17 p<0.01 
HSP73  +190 G/C 11q24 Ischemia tolerance SNP Fekete 2003 No G vs. C allele AKI … NS 
Haptoglobin Hp2-2, Hp2-1, 16q22 Fe metabolism, Phenotype Luo 2004 Yes Hp2-2 vs.  AKI OR=5.4 p=0.03 
 or Hp1-1  Anti-oxidant    Hp1-1/2-1      
*Not significant after adjustment for multiple comparisons; †calculated from published data; ‡for caucasian subgroup; §for african american subgroup;    
||for caucasian and african american subgroups, respectively       
Italics - results from multivariable analysis; NS = not significant       
   
 
Table 4 continued | Gene characteristics        
Gene Polymorphism Chromosome Functional Type of  Study Author's conclusion Comparison Association Magnitude of Significance 
   significance polymorphism  on association  Variable association of association 
            with AKI         
TNF-α  -308 G/A 6p21 Proinflammatory SNP Jaber 2004 Yes AA/AG vs. GG Mortality HR=2.47 p=0.04 
 -308 G/A    Stafford-Smith 2005 No AA/AG vs. GG Delta Cr … p=0.17† 
 -308 G/A    Gordon 2004 No A vs. G allele Renal SOFA score … NS 
 -308 G/A    Treszl 2002 No A vs. G allele AKI … NS 
 -238 G/A    Gordon 2004 No A vs. G allele Renal SOFA score … NS 
 +376 G/A    Stafford-Smith 2005 No AA/AG vs. GG Delta Cr … NS 
 +488 G/A    Stafford-Smith 2005 No AA/AG vs. GG Delta Cr … NS 
LTA  +365 C/G 6p21 Proinflammatory SNP Gordon 2004 No C vs. G allele Renal SOFA score … NS 
 +249 G/A    Gordon 2004 No G vs. A allele Renal SOFA score … NS 
IL-1b +3954 C/T 2q14 Proinflammatory SNP Treszl 2002 No T vs. C allele AKI … NS 
IL-6  -174 G/C 7p21 Inflammation modulator SNP Stafford-Smith 2005 No GG vs. CC/CG Delta Cr … NS 
 -174 G/C    Guadino 2002 Yes GG vs. CC/CG Delta Cr … p<0.0001 
 -174 G/C    Treszl 2002 No C vs. G allele AKI … NS 
 -572 G/C    Stafford-Smith 2005 No GG vs. CC/CG Delta Cr … p<0.0001*† 
 -597 G/A    Stafford-Smith 2005 No AA/AG vs. GG Delta Cr … NS 
TNFRSF1A  +1135 C/T 12p13 Anti-inflammatory SNP Gordon 2004 No C vs. T allele Renal SOFA score … NS 
 +36 A/G     Gordon 2004 No A vs. G allele Renal SOFA score … NS 
 -609 G/T    Gordon 2004 No G vs. T allele Renal SOFA score … NS 
TNFRSF1B  +1663 A/G 1p36 Anti-inflammatory SNP Gordon 2004 No A vs. G allele Renal SOFA score … NS 
 +676 T/G    Gordon 2004 No T vs. G allele Renal SOFA score … NS 
IL-10  -1082 G/A 1q31-32 Anti-inflammatory SNP Jaber 2004 Yes GG/GA vs. AA Mortality HR=0.36 p=0.03 
 -1082 G/A    Treszl 2002 No G vs. A allele AKI … NS 
VEGF -2578 C/A 6p12 Angiogenesis SNP Banyasz 2006 Yes AA vs. AC/CC AKI OR=0.2 p=0.021 
 -460 T/C    Banyasz 2006 No CC vs. CT/TT AKI … NS 
 +405 G/C    Banyasz 2006 No CC vs. GC/GG AKI … NS 
PAI-1  -675 4G/5G 7q21 Coagulation activation SNP Sirgo 2004 No 4G/4G vs. AKI … NS 
              4G/5G + 5G/5G     
*Not significant after adjustment for multiple comparisons; †For caucasian subgroup       
Italics - results from multivariable analysis; NS = not significant       
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+242C/T; Haptoglobin Hp2-2, 2-1 or 1-1; Heat Shock Protein 72 (HSP72) +1267A/G; 
Apolipoprotein E (APO E) e2/e3/e4; Angiotensin Converting Enzyme (ACE) I/D; TNF-
 -308G/A; IL-6 -174G/C; Interleukin-10 (IL-10) -1082G/A; Vascular Endothelial 
Growth Factor (VEGF) -2578C/A) were found to have significant associations in 
individual studies.(17, 19, 23, 32-36) Only one polymorphism, APO E e2/e3/e4, 
had an association with AKI demonstrated in multiple studies. 
 
Cholesterol Metabolism Genes - Apolipoprotein E 
 
Isbir et al.(23) found that in patients undergoing coronary artery bypass grafting 
(CABG), carriers of the APO E e4 allele had a decreased risk of AKI compared 
with non-APO E e4 patients (unadjusted odds ratio (OR)=0.18, p=0.002). Chew et 
al.(33) found the same result in a similar population, as those with the e4 allele 
had a smaller postoperative change in creatinine compared to those with e3 and 
e2 alleles (p=0.015 vs. e3, p=0.038 vs. e2), even after adjustment for preoperative 
creatinine, age, bypass time, hypertension, diabetes and ejection fraction.  
Mackensen et al.(37), examining a similar group of 130 CABG patients, also 
found this allele to have a protective effect after adjustment for a given amount 
of ascending aortic atheroma burden.  However, without adjustment no 
association was found.  Finally, a large study of 1671 cardiac surgical patients by 
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Stafford-Smith et al.(13) found no significant association between APO E alleles 
and the degree of change of postoperative creatinine in Caucasian or African-
American populations. 
 
Oxidative Stress Genes 
 
In a study of 200 patients with mixed-cause AKI, Perianayagam et al.(36) 
examined the association of polymorphisms in NADPH Oxidase p22phox and 
Catalase, two enzymes involved with the regulation of reactive oxygen species, 
with dialysis and mortality. Individuals with the T allele in the NADPH Oxidase 
p22phox gene possessed a greater risk of dialysis or mortality (unadjusted 
OR=2.11).  This remained true after adjusting for race, gender, age, APACHE II 
score and CKD.  No association was demonstrated between the Catalase gene and 
AKI. This study was unique in that it is one of two studies that examined 
associations with firm outcomes, i.e., dialysis or mortality.(19, 36) 
 
Vasomotor Regulation Genes 
 
For the ACE I/D polymorphism three studies were identified, of which only one 
found significant associations with AKI. Isbir et al. found that patients with the 
   
18 
ACE D allele exhibited increased risk of AKI following CABG (unadjusted 
OR=2.37, p=0.021).  However, Stafford-Smith and colleagues also examined the 
ACE I/D polymorphism and found no association with AKI.(13) Another study 
of 110 very low birth weight (VLBW) infants also found no association.(24) 
 
No significant associations were found with other genes involved with 
vasomotor regulation, including Angiotensinogen (AGT), Angiotensin Receptor 1 
(AGTR1) and eNOS. 
 
Inflammatory and Anti-Inflammatory Genes 
 
Six different studies examined a total of fifteen polymorphisms in seven genes 
involved in inflammatory and anti-inflammatory pathways.  Jaber et al.(19), in a 
study of 61 patients with AKI requiring hemodialysis, found that high producers 
of TNF- (-308 A-allele carriers) possessed an increased risk of death after 
adjustment for APACHE II score (adjusted hazard ratio (HR)=2.5, p=0.04). 
However, three other studies searched for an association between this 
polymorphism and AKI incidence, but found none.(13, 18, 20)  
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The same study by Jaber et al.(19) also found that IL-10 intermediate/high 
producers (-1082 G-allele carriers) had a decreased risk of death after adjustment 
for the multiple organ failure score (adjusted HR=0.36, p=0.36). Treszl et al. also 
investigated this polymorphism in VLBW infants but found no association with 
AKI incidence.(20) 
 
The IL-6 -174G/C polymorphism was investigated in three studies, of which only 
Guadino et al.(17) found a significant association. This study found that in 
patients undergoing CABG, IL-6 -174GG carriers had significantly higher 
elevations in perioperative creatinine vs. non-GG carriers (p<0.0001). However, 
Stafford-Smith et al.(13) found no such association in a similar population, nor 
did Treszl et al.(20) in VLBW infants. 
 
Other Genes 
 
Luo et al.(35), in a population of 148 CABG patients, found that Haptoglobin 2-2 
phenotype was associated with an increased risk of AKI (OR=5.4, p=0.03). In the 
HSP72 gene, Fekete et al.(34) found that VLBW infants homozygous for the G 
allele were at increased risk for AKI (OR=3.17, p<0.01). This same group also 
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found that in the VEGF -2578 C/A polymorphism, VLBW infants homozygous for 
the A allele were protected against AKI (OR=0.2, p=0.021).(32) 
 
None of the remaining polymorphisms investigated were found to be 
significantly associated with AKI.(38, 39) 
 
Gene-gene Interactions  
 
There were four studies that investigated gene-gene interactions and their 
association with AKI. The combinations studied were mostly those that 
augmented inflammatory or down-regulated anti-inflammatory pathways (Table 
5). Wattanathum et al.(40) found that the CGG haplotype involving three 
separate polymorphisms in the IL-10 gene (-592 C/A, +734 A/G and +3367 G/A) 
was associated with a greater degree of AKI in patients with sepsis from 
pneumonia. They postulated that this genotype is associated with lower anti-
inflammatory IL-10 production, thus causing increased renal dysfunction. 
 
Jaber et al.(19) investigated whether the combination of pro-inflammatory alleles 
from the TNF- -308G/A and IL-10 -1082 G/A polymorphisms, namely the TNF- 
-308 AA and IL-10 -1082 AA/AG genotypes, were associated with an increased 
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risk for dialysis or death. They found that patients with these genotypes had an 
elevated risk for dialysis or death after adjustment for APACHE II score 
(adjusted HR=5.17, p=0.005).   
 
Table 5 | Gene combinations    
Study Gene polymorphism Author's conclusion Magnitude of Significance 
 combinations  on association association of association 
    with AKI     
Wattanathum 2005 IL-10 -592 C/A, +734 A/G and +3367 G/A yes … p=0.024 
Stafford-Smith 2005 eNOS +894 G/T and AGTR1 +1166 A/C no … p=0.006*‡ 
 IL-6 -572 G/C and TNF-α -308 G/A yes … p=0.05‡ 
 AGT +842 T/C and IL-6 -572 G/C yes … p=<0.0001‡ 
 APO E e4 and AGT +842 T/C no … p=0.03*‡ 
 AGTR1 +1166 A/C and APO E e4 no … p=0.02*‡ 
 eNOS +894 G/T and ACE I/D no … p=0.006*§ 
 AGT +842 T/C and APO E e2 no … p=0.03*§ 
Jaber 2004 IL-10 -1082 G/A and TNF-α -308 G/A yes HR=5.72 p=0.004 
Treszl 2002 TNF-α -308 G/A and IL-6 -174 G/C yes OR=6.07† p<0.01 
 TNF-α -308 G/A and IL-1b +3954 C/T no … NS 
 TNF-α -308 G/A and IL-10 -1082 G/A no … NS 
 IL-1b +3954 C/T and IL-6 -174 G/C no … NS 
 IL-1b +3954 C/T and IL-10 -1082 G/A no … NS 
  IL-10 -1082 G/A and IL-6 -174 G/C no … NS 
*Not significant after adjustment for multiple comparison; †calculated from published data  
‡for caucasian subgroup; §For african-american subgroup    
Italics - results of multivariable analysis    
 
 
Treszl et al.(20) also investigated the TNF- -308G/A polymorphism, but in 
combination with the IL-6 -174G/C polymorphism. VLBW infants who had a 
combination of the IL-6 -174C allele and the TNF- -308A allele were at increased 
risk for developing AKI (OR=6.07, p<0.01). This finding was supported by 
Stafford-Smith et al.(13) who investigated the interaction of the IL-6 -572G/C (in 
linkage disequilibrium with IL-6 -174C) and TNF- -308G/A polymorphisms and 
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found that the combination of IL-6 -572C and TNF- -308A alleles were weakly 
associated (p=0.05) with AKI in Caucasians. This study also investigated the 
interaction between AGT+842T/C and IL-6 -572G/C polymorphisms, and found 
the combination to be significantly associated with AKI (p<0.0001).   
 
Discussion 
 
While there have been several descriptive reviews on this topic,(41-43) to our 
knowledge this is the first systematic review of genetic determinants of AKI. In 
summary, we found that there is no single polymorphism that can be 
conclusively described as a risk factor in AKI. The general dearth of studies, the 
lack of confirmatory studies and their overall mediocre quality led us to this 
conclusion.  
 
Of the 35 individual polymorphisms whose association with AKI has been 
studied, only APO E e2/e3/e4 had a significant association in more than one 
study.(23, 33)  Apolipoprotein E is an important protein in lipid metabolism. It is 
a component of very low density lipoproteins (VLDL) and is the primary ligand 
for the LDL receptor in the liver. It has three isoforms, each of which is encoded 
by a different allele of the APO E gene, e2, e3 or e4. This gene has been found to 
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influence the development of several complex diseases, including Alzheimer’s 
disease and atherosclerosis.(44, 45)  Recent evidence points to a regulatory role of 
APO E in inflammatory responses and may thus be affecting a given patient’s 
susceptibility to AKI.(21, 46)  However, the positive association found in 3 
studies(23, 33, 37) was contradicted by the results from the largest, highest 
quality study by Stafford-Smith et al.(13)  While it may be the case that the power 
of this study to find an effect was diluted by the need to correct for multiple 
comparisons, nevertheless its findings cast strong doubt on the positive findings 
of the other studies.   Furthermore, the study by Mackensen et al only found the 
APO e4 allele to be protective after adjusting for ascending aortic atheroma 
burden; the association claimed by the authors here is especially weak given that 
no relationship was found after adjustment for aortic arch and descending aorta 
atheroma burden.  Therefore, while a future higher-powered study may find a 
role of APO E in AKI, current evidence is inadequate to make such a claim. 
 
Of the gene-gene interactions studied, the combination of the IL-6 -174G/C and 
TNF- -308G/A polymorphisms is the most promising, as evidence for an 
association has been reported in two separate studies.(13, 20)  The association 
between the TNF- -308 AA and IL-10 -1082 AA/AG genotypes with dialysis or 
mortality demonstrated by Jaber et al., also requires mentioning.(19) While this 
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association has yet to be replicated, the individual polymorphisms had small but 
significant associations with poor outcomes, and the combined gene-gene 
interaction was associated with a much higher risk than either polymorphism 
individually, an effect known as multiplicative interaction. This group also 
demonstrated phenotypic differences in ex-vivo production of TNF- and IL-10 
between genotypic groups, which lends biological plausibility to this linkage. 
 
These results however do not belie the major finding of this review, that thus far 
findings in this field have been inconsistent and contradictory.  There is 
significant inter-study heterogeneity of results, as seen here with APO E and 
other polymorphisms, such as TNF- -308G/A and IL-6 -174G/C.  Causes for such 
heterogeneity include the large number of comparisons performed, which 
significantly increases the number of associations found by chance.(47)  
Population stratification from ethnic admixture, variable linkage disequilibrium 
and population specific gene-gene or gene-environment interactions are also 
potential sources of heterogeneity.  Therefore, it is recommended for authors to 
independently verify their results in an independent sample group prior to 
publication.(48)  This was an area that was found to be particularly lacking in the 
studies included within this systematic review (figure 1).  This important 
mechanism of quality control is especially necessary given that initial studies 
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tend to show more impressive associations then subsequent research, a problem 
that is particularly endemic in genetic association research.(27, 49) 
 
Indeed, the problem of false-positive reports has the potential to derail any 
potential research in this field before it has truly had a chance to begin.  It is for 
this reason that evaluating the quality of a genetic association study is critical in 
determining whether the association claimed by the authors is indeed true.  In 
addition to the independent replication of results, other important standards 
would include explicit demonstration of genotyping techniques and quality 
controls, adequate correction for multiple comparisons and evaluation of 
deviations from Hardy-Weinberg equilibrium.  Recommendations on study 
design and quality control methods for genetic association studies have recently 
been published by the NCI-NHGRI Working Group on Replication in 
Association Studies.(27)  Adherence to these standards will ensure that 
associations found in future studies are robust and durable. 
 
Another problem that we have found is one that is somewhat unique to AKI, that 
is the lack of a gold standard outcome which has also contributed to study 
heterogeneity.(50)  We found 5 different definitions of AKI in the studies found 
by our search; such variability increases the number of spurious associations and 
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makes inter-study comparison difficult. Use of well-defined criteria, such as the 
RIFLE (Risk of renal dysfunction, Injury to the kidney, Failure of kidney 
function, Loss of kidney function and End-stage kidney disease) or AKIN (Acute 
Kidney Injury Network) criteria will decrease heterogeneity and facilitate 
comparisons in future investigations.(30, 51) Even in this case however, caution 
is advised, in that both the RIFLE and AKIN criteria were formed in order to 
maximize sensitivity for AKI.  In particular, use of the most sensitive categories 
of these classification systems would result in unacceptable dilution of case 
groups with false positive subjects.  Therefore, we recommend using stage 2 of 
the AKIN criteria (a 200% to 300% increase in serum creatinine, or <0.5mL/kg 
urine output for 12 hours) as a cutoff, which would allow the creation of case 
groups that are both highly specific and have a well-defined phenotype. 
Studying outcomes such as dialysis or mortality would also alleviate this 
problem; however, due to the rarity of such events, an adequately powered 
study examining such outcomes may not be feasible. 
 
Novel biomarkers of kidney injury that are currently under study are another 
potential tool to be used in creating a highly specific AKI phenotype.  These 
biomarkers, unlike creatinine (which is a marker of the glomerular filtration rate, 
or GFR), are indicators of cell injury, particular that of tubular cells.(52)  The best 
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studied of these biomarkers is Neutrophil Gelatinase-associated Lipocalin 
(NGAL), which animal studies have shown to be an early marker of ischemic 
and nephrotoxic kidney injury.(53)  This biomarker has also been shown as a 
potential AKI marker in humans that is detectable in both serum and urine.(54, 
55)  Another marker, interleukin-18 (IL-18), is a mediator of ischemic AKI and 
has been studied in multiple clinical scenarios of AKI.(56-58)  As evidence 
accumulates for the role of these and other novel biomarkers in AKI, they can be 
incorporated into existing AKI definitions and be used to further increase case 
group specificity.(52, 54)   
 
Our study has limitations in several regards.  This systematic review is 
vulnerable to several types of bias, the first being publication bias.(59)  The 
literature has an inherent bias towards the publication of studies that find 
positive results.(60)  Negative studies may take longer to reach print, if at all.(61)  
We made no attempt to retrieve unpublished data, as there is no way to know 
whether such efforts would have successfully corrected the bias; indeed, 
including such data may even worsen the problem.(59) Therefore, despite using 
systematic methods and a highly sensitive search strategy, this may be a non-
representative sample of existing genetic association studies of AKI.  
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Another potential limitation is analysis reporting bias caused by researchers who 
report (or are forced to report due to space limitations) only a portion of their 
analyses.(62) This is especially salient in the reporting of gene-gene interactions, 
where many combinations of genetic polymorphisms may have been analysed 
for association but never reported.  
 
In conclusion, our present understanding of AKI suggests that genetic 
heterogeneity in pathways that regulate vascular and inflammatory responses to 
injury provide a plausible explanation for individual variability in susceptibility 
to AKI.  Continued efforts in this field are important, as finding genetic risk 
factors will allow us to identify patients at risk and implement preventive 
therapies.  Identification of culprit genes may also elucidate the true 
pathophysiology of AKI.  Although some genes show promise, existing 
candidate gene studies have been unable to find conclusive evidence to confirm 
any association.  
 
An alternative approach will be to use genome-wide association (GWA) studies.  
This technique has been harnessed to successfully investigate genetic 
vulnerabilities in complex diseases like macular degeneration and diabetes.(15, 
63)   GWA studies have the advantages of searching for candidate 
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polymorphisms unhindered by previous hypotheses and greater power in 
demonstrating the effects of gene-gene interactions or high risk haplotypes.(64)  
This is especially important for complex disorders, where increased genetic risk 
may be from several different polymorphisms acting together.  A pitfall is that 
GWA studies have unprecedented potential for false-positive results given the 
immense number of statistical tests performed; this problem can be somewhat 
alleviated by multistage designs and stringent requirements for statistical 
significance.(64)  Nevertheless, the success of future work will likely depend on 
harnessing this revolutionary technique and the application of a true consensus 
definition of AKI. 
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Figure 2 | Percentage of all studies reviewed that achieved each of the ten quality criteria*
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